CareFirst Family of health care plans

CVS caremark™

Entyvio

Prior Authorization Request

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: ______________________________ **Date**: ________________________________
Patient's ID: ________________________________ **Patient's Date of Birth:** ________________
Physician's Name: ____
Specialty: __________________________________ **NPI#:** _________________________________
Physician Office Telephone: __________________ **Physician Office Fax:** ___________________
Request Initiated For: _______________________

1. Has the patient been diagnosed with any of the following?
   ❑ Moderately to severely active Crohn's disease (CD)
   ❑ Moderately to severely active ulcerative colitis (UC)
   ❑ Other ____

2. What is the ICD-10 code? ________________

Section A: Preferred Product

3. These are the primary preferred products for which coverage is provided for treatment of the following conditions:
   a) Crohn's disease (CD): **Humira (primary); Cimzia (secondary)***
   b) Ulcerative colitis (UC): **Humira (primary); Simponi (secondary)***
   Note: Secondary preferred products for CD and UC are Cimzia and Simponi, respectively. These preferred product options only apply to members who have had a documented inadequate response or intolerable adverse event with Humira.

   Can the patient's treatment be switched to a preferred product?
   ❑ Yes - Please specify: ______________ ***If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.***
   ❑ No
   ❑ Not applicable - Requested for condition not listed above, *skip to Section B: All Requests*

4. Is this request for continuation of therapy with the requested product? ❑ Yes ❑ No *If No, skip to #6*

5. Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer Yes. ❑ Yes ❑ No *If No, skip to Section B: All Requests*

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Entyvio VF, ACSF SGM - 2/2018.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association

6. Has the patient had a documented inadequate response or intolerable adverse event with any of the following preferred products? Please indicate ALL that apply. ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   ❑ Cimzia: ❑ Inadequate response ❑ Intolerable adverse event
   ❑ Humira: ❑ Inadequate response ❑ Intolerable adverse event
   ❑ Simponi: ❑ Inadequate response ❑ Intolerable adverse event
   ❑ None of the above
7. Does the patient have one of the following documented clinical reasons to avoid TNF inhibitors (Humira, Cimzia or Simponi)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   ❑ Yes - History of demyelinating disorder ❑ Yes - Autoantibody formation/lupus-like syndrome
   ❑ Yes - History of congestive heart failure ❑ Yes - Risk of lymphoma
   ❑ Yes - History of hepatitis B virus infection ❑ No - none of the above

Section B: All Requests

8. Is this request for continuation of therapy? ❑ Yes ❑ No *If No, skip to #12*
9. Is the patient currently receiving Entyvio through samples or a manufacturer's patient assistance program?
   ❑ Yes ❑ No ❑ Unknown *If Yes or Unknown, skip to #12*
10. How long has the patient been receiving the requested medication? ______________ months
    If less than 4 months, no further questions.
11. Has the patient achieved or maintained positive clinical response to treatment as evidenced by low disease activity or improvement in signs and symptoms? *If Yes, no further questions* ❑ Yes ❑ No
12. Has the patient received any of the following medications?
    If Yes, please indicate the most recent medication and skip to diagnosis section.
    ❑ Cimzia ❑ Humira ❑ Inflectra ❑ Remicade ❑ Renflexis ❑ Simponi ❑ Stelara ❑ Tysabri ❑ No
13. Has the patient undergone pretreatment screening for latent tuberculosis (TB) infection with either a TB skin test or an interferon gamma release assay (e.g., QFT-GIT, T-SPOT.TB)? ❑ Yes ❑ No

Section C: Crohn's Disease

14. Has the patient tried and had an inadequate response to at least one conventional therapy option?
    If Yes, indicate below and no further questions.
    ❑ Yes - Sulfasalazine (Azulfidine, Sulfazine) ❑ Yes - Azathioprine (Azasan, Imuran)
    ❑ Yes - Mesalamine, oral (Asacol, Pentasa, Delzicol, Lialda) ❑ Yes - Mercaptopurine (Purinethol)
    ❑ Yes - Metronidazole (Flagyl) ❑ Yes - Methotrexate
    ❑ Yes - Ciprofloxacin (Cipro) ❑ Yes - Methylprednisolone (Solu-Medrol)
    ❑ Yes - Prednisone ❑ Yes - Rifaximin (Xifaxan)
    ❑ Yes - Budesonide (Entocort EC) ❑ No
15. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mesalamine [Asacol, Delzicol, Lialda, Pentasa], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan])? *If Yes, no further questions*
    ❑ Yes ❑ No
16. Has the patient had an inadequate response to a TNF-alpha inhibitor indicated for the treatment of CD (e.g., Cimzia, Humira, Remicade)? *If Yes, no further questions* ❑ Yes ❑ No
17. Does the patient have a contraindication or intolerance to a TNF-alpha inhibitor indicated for the treatment of CD (e.g., Cimzia, Humira, Remicade)? ❑ Yes ❑ No

Section D: Ulcerative Colitis

18. Has the patient tried and had an inadequate response to at least one conventional therapy option?
    If Yes, indicate below and no further questions.
    ❑ Yes - Azathioprine (Azasan, Imuran)

❑ Yes - Corticosteroid (e.g., budesonide [Entocort, Uceris], hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone)
❑ Yes - Cyclosporine (Sandimmune)
❑ Yes - Mesalamine (e.g., Asacol, Lialda, Pentasa, Canasa, Rowasa)
❑ Yes - Mercaptopurine (Purinethol)
❑ Yes - Sulfasalazine
❑ Yes - Tacrolimus (Prograf)
❑ Yes - Metronidazole (Flagyl) or Ciprofloxacin (Cipro) (for pouchitis only)
❑ No

19. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid [e.g., budesonide [Entocort, Uceris], hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone], cyclosporine [Sandimmune], mesalamine [Asacol, Lialda, Pentasa, Canasa, Rowasa], mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf], metronidazole/ciprofloxacin [for pouchitis only])? *If Yes, no further questions* ❑ Yes ❑ No

20. Has the patient had an inadequate response to a TNF-alpha inhibitor indicated for the treatment of UC (e.g., Humira, Remicade, Simponi)? *If Yes, no further questions* ❑ Yes ❑ No

21. Does the patient have a contraindication or intolerance to a TNF-alpha inhibitor indicated for the treatment of UC (e.g., Humira, Remicade, Simponi)? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X____

Prescriber or Authorized Signature **Date (mm/dd/yy)**